Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Insilico Medicine
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
August 20, 2026
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
August 20, 2026
AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
August 19, 2026
Insilico Medicine Launches the Industry’s First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
August 19, 2026
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
August 18, 2026
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
August 18, 2026
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform
August 17, 2026
Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
May 26, 2026
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
May 12, 2026
Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
April 28, 2026
1
2
3
Next Page
→